Silexion Therapeutics Corp (SLXN)
| Market Cap | 897.31K -99.1% |
| Revenue (ttm) | n/a |
| Net Income | -11.91M |
| EPS | -8.96 |
| Shares Out | 3.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,155,740 |
| Open | 0.2900 |
| Previous Close | 0.4988 |
| Day's Range | 0.2310 - 0.2900 |
| 52-Week Range | 0.2310 - 22.3600 |
| Beta | -0.29 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+2,127.17%) |
| Earnings Date | May 26, 2026 |
About SLXN
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for SLXN stock is "Strong Buy" and the 12-month stock price target is $6.0.
News
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
Grand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) thera...
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-I expression following SIL204 treatment in human pancreatic and non-small cell lung cancer cells har...
Silexion Therapeutics initiates GMP clinical batch manufacturing of SIL204
Silexion Therapeutics (SLXN) announced the initiation of good manufacturing practice, or GMP, clinical batch manufacturing of SIL204, the company’s siRNA therapy targeting mutated KRAS, in support of ...
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with global leading manufacturing partner Catalent at its Europe...
Silexion Therapeutics submits SIL204 clinical trial application to Germany
Silexion Therapeutics (SLXN) announced the recent successful submission of a clinical trial application, or CTA, to Germany for its planned Phase 2/3 clinical trial of its lead, small interfering RNA…
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer
CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany serving as Reference Member State for the EU program CTA submission positions Si...
Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204
Silexion Therapeutics (SLXN) announced that it has received formal approval from the Israeli Ministry of Health to initiate its Phase 2/3 clinical trial evaluating SIL204 for the treatment of locally…
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting hi...
Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer...
Silexion Therapeutics urges shareholders to vote ahead of EGM
Silexion Therapeutics (SLXN) reminds its shareholders of the upcoming Extraordinary General Meeting of Shareholders, scheduled to be held on March 16, 2026. At the EGM, shareholders will be asked to…
Silexion Therapeutics issues letter to shareholders
Silexion Therapeutics (SLXN) released a letter to shareholders from Chairman and Chief Executive Officer, Ilan Hadar. “2025 was a transformational year for Silexion Therapeutics. We positioned our lea...
Silexion submits Phase 2/3 trial application to Israel for SIL204
Silexion Therapeutics (SLXN) announced the initiation of its regulatory application in Israel for its planned Phase 2/3 clinical trial of SIL204 in patients with locally advanced pancreatic cancer, LA...
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed
Silexion Therapeutics initiated with a Buy at Litchfield Hills
Litchfield Hills analyst Theodore O’Neill initiated coverage of Silexion Therapeutics (SLXN) with a Buy rating and $6 price target Silexion Therapeutics is targeting unmet need in KRAS-driven cancers ...
Silexion receives positive feedback from German Health Authority for SIL204
Silexion Therapeutics (SLXN) announced that it has received formal written Scientific Advice from the German Federal Institute for Drugs and Medical Devices regarding the proposed design of the Compan...
Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference
Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced tha...
Silexion Therapeutics completes toxicology studies for SIL204
Silexion Therapeutics (SLXN) announced the successful completion of toxicology studies for SIL204, the Company’s next-generation RNA silencing therapy targeting mutated KRAS oncogenes, ahead of its pl...
Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer
Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany
Silexion Therapeutics reports Q3 EPS $2.88 vs $274.25 last year
Ilan Hadar, Chairman and Chief Executive Officer of Silexion, commented: “The third quarter marked a period of strong scientific progress and continued operational momentum for Silexion. With new prec...
Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204's exceptional efficacy across multiple human cancer cell ...
Silexion Therapeutics files to sell 1.29M ordinary shares for holders
Also files to sell up to 372 warrants for holders.
Silexion Therapeutics announces new data in SIL204
The company states: “Silexion Therapeutics (SLXN) announced that SIL204 has demonstrated activity against eleven human cell lines originating from 5 different organ cancer sites, each with a specific ...
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer
New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations
Silexion Therapeutics files $100M mixed securities shelf
16:32 EDT Silexion Therapeutics (SLXN) files $100M mixed securities shelf
Silexion Therapeutics regains compliance with Nasdaq listing requirements
Silexion Therapeutics (SLXN) announced that it has received written notification from The Nasdaq Stock Market confirming that the Company has regained compliance with both Nasdaq Listing Rules 5550(a)...